 |
 |
 |
 |
 |
 |
 |
 |
Tercica is a biotechnology company with a unique focus:
To develop and commercialize new products to help patients with endocrine and metabolic diseases. Partnership and innovation are central to our success.
To develop and commercialize new products to help patients with endocrine and metabolic diseases. Partnership and innovation are central to our success.
People with endocrine and metabolic diseases deserve better treatment options.
Tercica® is the first and only biotechnology company whose sole goal is to fully embrace this underserved patient population. In our first five years, we launched two novel products. More new product candidates intended to treat patients with endocrine and metabolic disorders are in our development pipeline right now.
Our revenues are growing, our roadmap for growth is clear, and we have exciting career opportunities for experienced people who share our passion for improving endocrine and metabolic health. Our company and professional relationships are guided by four core values: Partnership, accountability, genuineness, and excellence.
Tercica® is the first and only biotechnology company whose sole goal is to fully embrace this underserved patient population. In our first five years, we launched two novel products. More new product candidates intended to treat patients with endocrine and metabolic disorders are in our development pipeline right now.
Our revenues are growing, our roadmap for growth is clear, and we have exciting career opportunities for experienced people who share our passion for improving endocrine and metabolic health. Our company and professional relationships are guided by four core values: Partnership, accountability, genuineness, and excellence.
A message to the ALS Community from Tercica. Read more »
We launched the world's first long-term therapy for children with short stature due to severe Primary IGFD.
Our new product for adults with acromegaly simplifies treatment with a ready-to-use, prefilled syringe.